Rescue of susceptibility to second-line drugs in resistant clinical isolates of Mycobacterium tuberculosis

Página do item simplificado
dc.contributor.authorMaringolo-Ribeiro, Camila [UNESP]
dc.contributor.authorGrecco, Julia A. [UNESP]
dc.contributor.authorBellato, Debora L. [UNESP]
dc.contributor.authorAlmeida, Aryadne L.
dc.contributor.authorBaldin, Vanessa P.
dc.contributor.authorCaleffi-Ferracioli, Katiany R.
dc.contributor.authorPavan, Fernando R. [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Estadual de Maringá (UEM)
dc.date.accessioned2022-04-28T18:45:59Z
dc.date.available2022-04-28T18:45:59Z
dc.date.issued2022-03-23
dc.description.abstractAim: Antibiotic resistance is one of the biggest threats to global health, and this study aimed better understand how the efflux pumps are related to this process in tuberculosis clinical isolates. Results: The combination of antibiotics plus efflux pumps (EP) inhibitors was able to restore the susceptibility of clinical isolates in 100% of aminoglycosides resistance and 33.3% of the fluoroquinolones resistance. The relative expression of EP genes in pre-extensively drug-resistant isolates showed an increase of up to 1000-times. Conclusion: The rescue of susceptibility in the presence of EP inhibitors, the increased of activity and expression of the EP genes alert that the inhibition of EP can reduce the selection of resistant strains and improve treatment.en
dc.description.affiliationSao Paulo State Univ UNESP, Sch Pharmaceut Sci, TB Res Lab, Araraquara, SP, Brazil
dc.description.affiliationState Univ Maringa UEM, Dept Clin Anal & Biomed, Maringa, Parana, Brazil
dc.description.affiliationUnespSao Paulo State Univ UNESP, Sch Pharmaceut Sci, TB Res Lab, Araraquara, SP, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipSao Paulo State University
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipIdFAPESP: FAPESP 2018/02344-2
dc.description.sponsorshipIdFAPESP: 2018/12135-1
dc.description.sponsorshipIdFAPESP: 2020/13497-4
dc.description.sponsorshipIdCAPES: 001
dc.format.extent511-527
dc.identifierhttp://dx.doi.org/10.2217/fmb-2021-0215
dc.identifier.citationFuture Microbiology. London: Future Medicine Ltd, v. 17, n. 7, p. 511-527, 2022.
dc.identifier.doi10.2217/fmb-2021-0215
dc.identifier.issn1746-0913
dc.identifier.urihttp://hdl.handle.net/11449/218993
dc.identifier.wosWOS:000772612000001
dc.language.isoeng
dc.publisherFuture Medicine Ltd
dc.relation.ispartofFuture Microbiology
dc.sourceWeb of Science
dc.subjectaminoglycoside
dc.subjectantibiotic resistance
dc.subjectCCCP
dc.subjectefflux pumps
dc.subjectfluoroquinolone
dc.subjectgene expression
dc.subjectreserpine
dc.subjectRT-PCR
dc.subjecttuberculosis
dc.subjectverapamil
dc.titleRescue of susceptibility to second-line drugs in resistant clinical isolates of Mycobacterium tuberculosisen
dc.typeArtigo
dcterms.rightsHolderFuture Medicine Ltd
unesp.departmentCiências Biológicas - FCFpt

Arquivos

Coleções

Araraquara - FCF - Faculdade de Ciências Farmacêuticas